Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06013475 · ClinicalTrials.gov registry record
An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 1,375
- Enrollment target
NCT06013475: Completed study, sponsored by Bayer.
NCT06013475 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 1,375 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06013475 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 1,375 participants
- Enrollment target
Study Summary
This is an observational cohort study in men with non-metastatic castration-resistant prostate cancer who received their usual treatment, which is 'Androgen receptor inhibitors' (ARIs) including darolutamide, enzalutamide, and apalutamide. The main purpose of this study is to collect data on the length of time men with nmCRPC continued treatment with darolutamide, enzalutamide, or apalutamide as prescribed by their doctors. Researchers will only include men who had not been treated with any new type of medication that blocks the action of hormones. The data will come from an electronic health record database called Precision Point Specialty (PPS) Prostate Cancer Electronic Medical Record (EMR) for men in the United States of America. EMR data will be verified and supplemented via patient chart review. Data collected will be from January 2019 to September 2023. .
Interventions
- DRUG Apalutamide
- DRUG Enzalutamide
- DRUG Darolutamide (BAY 1841788)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,375 participants |
| Start Date | 2023-08-31 |
| Est. Completion | 2024-10-28 |
What the finished NCT06013475 record still lists
NCT06013475 is an observational study that tracks outcomes without assigning an intervention. Its 1,375 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 3 interventions - of which Apalutamide is the first listed.
NCT06013475 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06013475 about?
NCT06013475 is a clinical study titled "An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings". This is an observational cohort study in men with non-metastatic castration-resistant prostate cancer who received their usual treatment, which is 'Androgen receptor inhibitors' (ARIs) including darolutamide, enzalutamide, and apalutamide. The main purpose of this study is to collect data on the le...
What is the current status of trial NCT06013475?
This trial is currently completed. The enrollment target is 1,375 participants. The study started on 2023-08-31. Estimated completion is 2024-10-28.
What interventions are being tested in trial NCT06013475?
The interventions under investigation include: Apalutamide (DRUG), Enzalutamide (DRUG), Darolutamide (BAY 1841788) (DRUG).
Who is sponsoring clinical trial NCT06013475?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06651281 · 1,380 participants · Phase 3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- NCT07256392 · 1,370 participants · Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- NCT04489238 · 1,366 participants
Collection of Information to Better Understand Young Onset Colorectal Cancer
- NCT02677064 · 1,365 participants
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI